Wanbury Q1 Results QoQ Revenue Decline of 5.94% and YoY Drop of 10.38%

Wanbury Quarterly Growth Overview 

Wanbury Q1 Results: In the first quarter of 2024, Wanbury’s financial performance shows a decline in many key areas compared to both the previous quarter and the same quarter last year. The total revenue was 131.11 crores, which is a slight decrease of 1.40% from the previous quarter and a larger drop of 10.38% from last year. 

Wanbury’s Selling, general, and administrative expenses increased by 21.59% from the previous quarter to 25.15 crores and were also up by 19.30% from last year. Depreciation and amortization costs saw a small increase of 7.19% from the last quarter, reaching 3.29 crores, but only a slight rise of 3.27% from last year.

Wanbury’s other operating expenses increased by 20.66% from the previous quarter to 28.73 crores and by 7.08% from last year. Total operating expenses went up by 0.77% from the previous quarter but fell by 9.33% from last year. Operating income dropped significantly by 26.78% from the previous quarter to 7.69 crores and by 24.38% from last year. 

Wanbury’s net income before taxes increased by 12.91% from the previous quarter but fell dramatically by 79.21% from last year. Net income saw a small increase of 1.96% from the last quarter but a large decline of 77.87% from last year. Diluted normalized EPS decreased by 27.91% from the previous quarter and by 78.32% from last year. Overall, Wanbury’s financial results show a challenging quarter with significant drops in earnings and increased expenses.

Here are Wanbury's Q1 financial results, with figures presented in crores:

(All figures in crores except per share values)

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Wanbury Q1 Results

Wanbury’s financial results for the quarter ending June 30, 2024, show several key figures. Their revenue from operations was ₹13,110.82 lakhs, which is lower compared to the ₹14,628.54 lakhs they earned in the same quarter last year. The total income for this quarter was ₹13,205.28 lakhs, including other income, which is slightly less than last year's ₹14,690.20 lakhs.

Wanbury's expenses include costs for materials, purchases, and employee benefits. The cost of materials consumed was ₹6,419.91 lakhs, down from ₹8,274.69 lakhs a year ago. They also spent ₹327.55 lakhs on stock-in-trade and had a slight reduction in inventory costs. Employee benefits cost ₹2,515.16 lakhs, and finance costs were ₹759.26 lakhs. They spent ₹328.87 lakhs on depreciation and ₹2,872.77 lakhs on other expenses.

Wanbury’s total expenses were ₹13,050.54 lakhs, leading to a profit before tax of ₹103.74 lakhs. After accounting for taxes, their profit after tax was ₹103.74 lakhs. The company reported a comprehensive income of ₹76.48 lakhs for this quarter. The earnings per share were ₹0.32, reflecting the company's performance.

Here’s the Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2024 (₹ in Lakhs)

Wanbury Financial Performance

The Wanbury table shows key financial information about the company's stock. The market cap, which is the total value of all the company's shares, is ₹771 Crore. The current price of one share is ₹236. The stock has traded between a high of ₹254 and a low of ₹51.2. The Price-to-Earnings (P/E) ratio is 28.6, which helps investors understand how much they are paying for each rupee of earnings.

Here's the financial data in table format:

Quarterly Results

Wanbury's sales were ₹145.50 crores in December 2023, with expenses of ₹124.35 crores, leading to an operating profit of ₹21.15 crores. Their operating profit margin was 14.54%, showing strong profitability. Other income was ₹0.69 crores, and interest costs were ₹8.26 crores. The profit before tax was ₹10.26 crores, and net profit was ₹10.27 crores, with earnings per share (EPS) of ₹3.14. 

Here's the data for December 2023, March 2024, and June 2024 with their particulars:

About Wanbury

Wanbury is a leading pharmaceutical company in India, recognized among the top 50 companies in the country by ORG-IMS. It has a significant presence in the global Active Pharmaceutical Ingredient (API) market and the domestic branded formulations sector. Wanbury focuses on producing and marketing APIs, with over 13 different API products. It is especially noted for being the largest manufacturer of Metformin, producing over 8500 tons annually.

Wanbury has a strong market presence in Europe and the United States, particularly for APIs like Tramadol and Sertraline. Wanbury exports its products to more than 50 countries, with 65% of its exports going to regulated markets. The company operates two US-FDA-approved multi-product API facilities and has another plant for semi-regulated markets. Wanbury is a trusted supplier to some of the world's top five generic drug manufacturers.

In addition to APIs, Wanbury has a broad range of formulations available across India. The company offers around 70 brands in various medical fields, including gynecology, orthopedics, anti-diabetic treatments, nutraceuticals, and more. Its products cover multiple therapeutic areas like gastrointestinal issues, stroke surgery, antibiotics, cough and cold remedies, anti-inflammatory drugs, and general healthcare.